Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Sarcoma × nilotinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17 Leukemia 6 Philadelphia Chromosome 3 Leukemia, Myeloid, Chronic-Phase 3 Gastrointestinal Stromal Tumors 3 Neoplasms 2 Myeloproliferative Disorders 2 Bronchiolitis Obliterans Syndrome 2 Sarcoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms by Histologic Type 1 Neoplasm Metastasis 1 Leukemia, Myeloid 1 Hematologic Diseases 1 Bone Marrow Diseases 1

Interventions

Doxorubicin 22 Ifosfamide 19 Radiotherapy 14 Vincristine 9 Etoposide 9 Filgrastim 8 Cyclophosphamide 8 Trabectedin 7 Dactinomycin 7 pazopanib 4 Cisplatin 4 Topotecan 3 Radiation 3 Irinotecan 3 Granulocyte Colony-Stimulating Factor 3 Chemotherapy, Adjuvant 3 sargramostim 2 etoposide phosphate 2 eribulin 2 Observation 2 Methotrexate 2 Mesna 2 Imatinib Mesylate 2 Gemcitabine 2 Docetaxel 2 Dexrazoxane 2 Dacarbazine 2 trofosfamide 1 trioctyl phosphine oxide 1 trametinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡